Media

CEO Podcast Interview: The Genetic Revolution in Treating Neurodegenerative Disease with Martin Jacko

Martin Jacko is the founder of Aperture Therapeutics, a startup developing ASO (Antisense Oligonucleotide) based therapies for neurodegenerative diseases like ALS. Aperture's approach is unique in how they are guided by genetic profiles of individuals who are naturally resilient to neurodegenerative diseases.

Yahoo Finance: Aperture Therapeutics Awarded Mission BioCapital 2024 Platinum Ticket

Mission BioCapital (MBC), in partnership with sponsors Eli Lilly and Company (Lilly), Ono Venture Investment (OVI), Alloy Therapeutics, and our newest sponsor, HitGen, announced today that applications are open internationally for the 2025 Platinum Program. MBC's Platinum Program aims to advance high-potential life sciences start-up companies by providing pre-seed funding, global laboratory space, expert mentorship, and discovery services to accelerate their launch and initial development